House passes bill to cap out-of-pocket insulin costs
NBCAPR 2022
This will ensure that Americans are never denied access to the life-saving medication because of economic inequality. Prices of insulin are massively inflated for consumers and complaints about price-fixing only play into the hands of Big Pharma.
Although this may seem compassionate, it doesn't address the core issue and instead simply shifts the cost to health insurers and employers, inevitably leading to higher premiums. It also risks increasing the price of other drugs because the legislation fails to reform the rebate system.